{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T04:01:01Z","timestamp":1785038461314,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-026-73871-x","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:15:41Z","timestamp":1780114541000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inference of upstream-mutation and metabolomic-signature causality identifies prognostic biomarkers and therapeutic targets in pancreatic cancer"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2034-6351","authenticated-orcid":false,"given":"Feng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3054-5592","authenticated-orcid":false,"given":"Xiaoying","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5690-8302","authenticated-orcid":false,"given":"Xingting","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2409-041X","authenticated-orcid":false,"given":"Ye","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2615","authenticated-orcid":false,"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9521-5124","authenticated-orcid":false,"given":"Ruijun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5664-7757","authenticated-orcid":false,"given":"Min","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9987-7916","authenticated-orcid":false,"given":"Xudong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-3160","authenticated-orcid":false,"given":"Hezhi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0947-5091","authenticated-orcid":false,"given":"Wei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"73871_CR1","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1177\/1756283X13478680","volume":"6","author":"PE Oberstein","year":"2013","unstructured":"Oberstein, P. E. & Olive, K. P. Pancreatic cancer: why is it so hard to treat? Ther. Adv. Gastroenterol. 6, 321\u2013337 (2013).","journal-title":"Ther. Adv. Gastroenterol."},{"key":"73871_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ctrv.2017.08.007","volume":"60","author":"M Chiaravalli","year":"2017","unstructured":"Chiaravalli, M., Reni, M. & O\u2019Reilly, E. M. Pancreatic ductal adenocarcinoma: state-of-the-art 2017 and new therapeutic strategies. Cancer Treat. Rev. 60, 32\u201343 (2017).","journal-title":"Cancer Treat. Rev."},{"key":"73871_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park, W., Chawla, A. & O\u2019Reilly, E. M. Pancreatic cancer: a review. JAMA 326, 851\u2013862 (2021).","journal-title":"JAMA"},{"key":"73871_CR4","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI59227","volume":"122","author":"MA Collins","year":"2012","unstructured":"Collins, M. A. et al. Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J. Clin. Investig. 122, 639\u2013653 (2012).","journal-title":"J. Clin. Investig."},{"key":"73871_CR5","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801\u20131806 (2008).","journal-title":"Science"},{"key":"73871_CR6","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/nature25459","volume":"554","author":"S Mueller","year":"2018","unstructured":"Mueller, S. et al. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes. Nature 554, 62\u201368 (2018).","journal-title":"Nature"},{"key":"73871_CR7","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of pancreatic ductal adenocarcinoma. Cancer Cell 32, 185\u2013203 (2017)."},{"key":"73871_CR8","doi-asserted-by":"publisher","first-page":"e173420","DOI":"10.1001\/jamaoncol.2017.3420","volume":"4","author":"ZR Qian","year":"2018","unstructured":"Qian, Z. R. et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 4, e173420 (2018).","journal-title":"JAMA Oncol."},{"key":"73871_CR9","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1158\/2159-8290.CD-15-0671","volume":"5","author":"RM Perera","year":"2015","unstructured":"Perera, R. M. & Bardeesy, N. Pancreatic cancer metabolism: breaking it down to build it back up. Cancer Discov. 5, 1247\u20131261 (2015).","journal-title":"Cancer Discov."},{"key":"73871_CR10","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.cell.2012.01.058","volume":"149","author":"H Ying","year":"2012","unstructured":"Ying, H. et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656\u2013670 (2012).","journal-title":"Cell"},{"key":"73871_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s41586-018-0235-7","volume":"558","author":"LV Danai","year":"2018","unstructured":"Danai, L. V. et al. Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558, 600\u2013604 (2018).","journal-title":"Nature"},{"key":"73871_CR12","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1053\/j.gastro.2019.01.039","volume":"156","author":"RP Sah","year":"2019","unstructured":"Sah, R. P. et al. Phases of metabolic and soft tissue changes in months preceding a diagnosis of pancreatic ductal adenocarcinoma. Gastroenterology 156, 1742\u20131752 (2019).","journal-title":"Gastroenterology"},{"key":"73871_CR13","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/ng.520","volume":"42","author":"J Dupuis","year":"2010","unstructured":"Dupuis, J. et al. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat. Genet. 42, 105\u2013116 (2010).","journal-title":"Nat. Genet."},{"key":"73871_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000504","volume":"5","author":"M Kolz","year":"2009","unstructured":"Kolz, M. et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet. 5, e1000504 (2009).","journal-title":"PLoS Genet."},{"key":"73871_CR15","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/nature09270","volume":"466","author":"TM Teslovich","year":"2010","unstructured":"Teslovich, T. M. et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466, 707\u2013713 (2010).","journal-title":"Nature"},{"key":"73871_CR16","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/ng.1073","volume":"44","author":"J Kettunen","year":"2012","unstructured":"Kettunen, J. et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 44, 269\u2013276 (2012).","journal-title":"Nat. Genet."},{"key":"73871_CR17","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/ng.2982","volume":"46","author":"SY Shin","year":"2014","unstructured":"Shin, S. Y. et al. An atlas of genetic influences on human blood metabolites. Nat. Genet. 46, 543\u2013550 (2014).","journal-title":"Nat. Genet."},{"key":"73871_CR18","doi-asserted-by":"publisher","first-page":"3602","DOI":"10.1016\/j.cell.2024.05.011","volume":"187","author":"DH Tran","year":"2024","unstructured":"Tran, D. H. et al. De novo and salvage purine synthesis pathways across tissues and tumors. Cell 187, 3602\u20133618 e3620 (2024).","journal-title":"Cell"},{"key":"73871_CR19","first-page":"2475","volume":"44","author":"Y Natsumeda","year":"1984","unstructured":"Natsumeda, Y., Prajda, N., Donohue, J. P., Glover, J. L. & Weber, G. Enzymic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. 44, 2475\u20132479 (1984).","journal-title":"Cancer Res."},{"key":"73871_CR20","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1016\/j.tibs.2024.08.005","volume":"49","author":"S Kim","year":"2024","unstructured":"Kim, S., Bhandari, R., Brearley, C. A. & Saiardi, A. The inositol phosphate signalling network in physiology and disease. Trends Biochem. Sci. 49, 969\u2013985 (2024).","journal-title":"Trends Biochem. Sci."},{"key":"73871_CR21","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.cmet.2020.10.012","volume":"33","author":"Y Gong","year":"2021","unstructured":"Gong, Y. et al. Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab. 33, 51\u201364 (2021).","journal-title":"Cell Metab."},{"key":"73871_CR22","doi-asserted-by":"crossref","unstructured":"Sun, T. et al. A combined oncogenic pathway signature of BRAF, KRAS and PI3KCA mutation improves colorectal cancer classification and cetuximab treatment prediction. Gut 62, 540 (2013).","DOI":"10.1136\/gutjnl-2012-302423"},{"key":"73871_CR23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature16965","volume":"531","author":"P Bailey","year":"2016","unstructured":"Bailey, P. et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature 531, 47\u201352 (2016).","journal-title":"Nature"},{"key":"73871_CR24","doi-asserted-by":"crossref","unstructured":"Li, Y. et al. Metabolic classification suggests the GLUT1\/ALDOB\/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep. Med. 4, 101162 (2023).","DOI":"10.1016\/j.xcrm.2023.101162"},{"key":"73871_CR25","doi-asserted-by":"publisher","first-page":"5031","DOI":"10.1016\/j.cell.2021.08.023","volume":"184","author":"L Cao","year":"2021","unstructured":"Cao, L. et al. Proteogenomic characterization of pancreatic ductal adenocarcinoma. Cell 184, 5031\u20135052 (2021).","journal-title":"Cell"},{"key":"73871_CR26","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1093\/annonc\/mdr561","volume":"23","author":"JL Humphris","year":"2012","unstructured":"Humphris, J. L. et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann. Oncol. 23, 1713\u20131722 (2012).","journal-title":"Ann. Oncol."},{"key":"73871_CR27","doi-asserted-by":"crossref","unstructured":"Aleksakhina, S. N. & Imyanitov, E. N. Cancer therapy guided by mutation tests: current status and perspectives. Int. J. Mol. Sci. 22, 10931 (2021).","DOI":"10.3390\/ijms222010931"},{"key":"73871_CR28","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20209730","volume":"17","author":"A Dugourd","year":"2021","unstructured":"Dugourd, A. et al. Causal integration of multi-omics data with prior knowledge to generate mechanistic hypotheses. Mol. Syst. Biol. 17, e9730 (2021).","journal-title":"Mol. Syst. Biol."},{"key":"73871_CR29","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1038\/ng1589","volume":"37","author":"EE Schadt","year":"2005","unstructured":"Schadt, E. E. et al. An integrative genomics approach to infer causal associations between gene expression and disease. Nat. Genet. 37, 710\u2013717 (2005).","journal-title":"Nat. Genet."},{"key":"73871_CR30","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.canlet.2021.09.026","volume":"524","author":"X Gao","year":"2022","unstructured":"Gao, X. et al. ETV4 promotes pancreatic ductal adenocarcinoma metastasis through activation of the CXCL13\/CXCR5 signaling axis. Cancer Lett. 524, 42\u201356 (2022).","journal-title":"Cancer Lett."},{"key":"73871_CR31","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1038\/ng.3984","volume":"49","author":"RM Meyers","year":"2017","unstructured":"Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779\u20131784 (2017).","journal-title":"Nat. Genet."},{"key":"73871_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13668-3","volume":"11","author":"I Martinez-Reyes","year":"2020","unstructured":"Martinez-Reyes, I. & Chandel, N. S. Mitochondrial TCA cycle metabolites control physiology and disease. Nat. Commun. 11, 102 (2020).","journal-title":"Nat. Commun."},{"key":"73871_CR33","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.7150\/ijbs.69526","volume":"18","author":"S Chen","year":"2022","unstructured":"Chen, S. et al. Enhanced pentose phosphate pathway activity promotes pancreatic ductal adenocarcinoma progression via activating YAP\/MMP1 axis under chronic acidosis. Int. J. Biol. Sci. 18, 2304\u20132316 (2022).","journal-title":"Int. J. Biol. Sci."},{"key":"73871_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.101966","volume":"6","author":"X Jiang","year":"2025","unstructured":"Jiang, X. et al. KRAS(G12D)-driven pentose phosphate pathway remodeling imparts a targetable vulnerability synergizing with MRTX1133 for durable remissions in PDAC. Cell Rep. Med. 6, 101966 (2025).","journal-title":"Cell Rep. Med."},{"key":"73871_CR35","doi-asserted-by":"publisher","first-page":"18075","DOI":"10.1074\/jbc.M117.788463","volume":"292","author":"S Srivastava","year":"2017","unstructured":"Srivastava, S. et al. Regulation of mitochondrial protein import by the nucleotide exchange factors GrpEL1 and GrpEL2 in human cells. J. Biol. Chem. 292, 18075\u201318090 (2017).","journal-title":"J. Biol. Chem."},{"key":"73871_CR36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1038\/s42003-022-04034-z","volume":"5","author":"N Neupane","year":"2022","unstructured":"Neupane, N. et al. Inter-organellar and systemic responses to impaired mitochondrial matrix protein import in skeletal muscle. Commun. Biol. 5, 1060 (2022).","journal-title":"Commun. Biol."},{"key":"73871_CR37","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1016\/j.ccell.2017.04.013","volume":"31","author":"Y Zhang","year":"2017","unstructured":"Zhang, Y. et al. A pan-cancer proteogenomic atlas of PI3K\/AKT\/mTOR pathway alterations. Cancer Cell 31, 820\u2013832 (2017).","journal-title":"Cancer Cell"},{"key":"73871_CR38","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960\u2013976 (2017).","journal-title":"Cell"},{"key":"73871_CR39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/s41568-019-0216-7","volume":"20","author":"G Hoxhaj","year":"2020","unstructured":"Hoxhaj, G. & Manning, B. D. The PI3K\u2013AKT network at the interface of oncogenic signalling and cancer metabolism. Nat. Rev. Cancer 20, 74\u201388 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"73871_CR40","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","volume":"18","author":"D Mossmann","year":"2018","unstructured":"Mossmann, D., Park, S. & Hall, M. N. mTOR signalling and cellular metabolism are mutual determinants in cancer. Nat. Rev. Cancer 18, 744\u2013757 (2018).","journal-title":"Nat. Rev. Cancer"},{"key":"73871_CR41","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.canlet.2014.01.014","volume":"346","author":"WK Utomo","year":"2014","unstructured":"Utomo, W. K. et al. mTOR is a promising therapeutical target in a subpopulation of pancreatic adenocarcinoma. Cancer Lett. 346, 309\u2013317 (2014).","journal-title":"Cancer Lett."},{"key":"73871_CR42","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/bjc.2017.421","volume":"118","author":"Z Hassan","year":"2018","unstructured":"Hassan, Z. et al. MTOR inhibitor-based combination therapies for pancreatic cancer. Br. J. Cancer 118, 366\u2013377 (2018).","journal-title":"Br. J. Cancer"},{"key":"73871_CR43","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1136\/gutjnl-2013-306202","volume":"63","author":"CM Douglas","year":"2014","unstructured":"Douglas, C. M. et al. Targeting mTOR dependency in pancreatic cancer. Gut 63, 1481 (2014).","journal-title":"Gut"},{"key":"73871_CR44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.redox.2016.09.006","volume":"10","author":"W Chen","year":"2016","unstructured":"Chen, W. et al. Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer. Redox Biol. 10, 78\u201389 (2016).","journal-title":"Redox Biol."},{"key":"73871_CR45","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.ccell.2017.01.014","volume":"31","author":"Q Fan","year":"2017","unstructured":"Fan, Q. et al. A kinase inhibitor targeted to mTORC1 drives regression in glioblastoma. Cancer Cell 31, 424\u2013435 (2017).","journal-title":"Cancer Cell"},{"key":"73871_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.873131","volume":"13","author":"HT Wu","year":"2022","unstructured":"Wu, H. T. et al. Induced cell cycle arrest in triple-negative breast cancer by combined treatment of itraconazole and rapamycin. Front. Pharmacol. 13, 873131 (2022).","journal-title":"Front. Pharmacol."},{"key":"73871_CR47","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41586-022-05426-1","volume":"612","author":"M Schmitt","year":"2022","unstructured":"Schmitt, M. et al. Colon tumour cell death causes mTOR dependence by paracrine P2X4 stimulation. Nature 612, 347\u2013353 (2022).","journal-title":"Nature"},{"key":"73871_CR48","doi-asserted-by":"publisher","first-page":"18676","DOI":"10.18632\/aging.103958","volume":"12","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Identification of genomic alterations and associated transcriptomic profiling reveal the prognostic significance of MMP14 and PKM2 in patients with pancreatic cancer. Aging 12, 18676\u201318692 (2020).","journal-title":"Aging"},{"key":"73871_CR49","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/1097-0215(20001120)89:6<469::AID-IJC1>3.0.CO;2-L","volume":"89","author":"A Kawesha","year":"2000","unstructured":"Kawesha, A. et al. K-Ras oncogene subtype mutations are associated with survival but not expression of p53, p16(INK4A), p21(WAF-1), cyclin D1, erbB-2 and erbB-3 in resected pancreatic ductal adenocarcinoma. Int. J. Cancer 89, 469\u2013474 (2000).","journal-title":"Int. J. Cancer"},{"key":"73871_CR50","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.cmet.2017.03.008","volume":"25","author":"AS Husted","year":"2017","unstructured":"Husted, A. S., Trauelsen, M., Rudenko, O., Hjorth, S. A. & Schwartz, T. W. GPCR-mediated signaling of metabolites. Cell Metab. 25, 777\u2013796 (2017).","journal-title":"Cell Metab."},{"key":"73871_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27765-9","volume":"13","author":"D Wolrab","year":"2022","unstructured":"Wolrab, D. et al. Lipidomic profiling of human serum enables detection of pancreatic cancer. Nat. Commun. 13, 124 (2022).","journal-title":"Nat. Commun."},{"key":"73871_CR52","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s10654-023-01014-3","volume":"38","author":"S Naudin","year":"2023","unstructured":"Naudin, S. et al. Lipidomics and pancreatic cancer risk in two prospective studies. Eur. J. Epidemiol. 38, 783\u2013793 (2023).","journal-title":"Eur. J. Epidemiol."},{"key":"73871_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abh2724","volume":"7","author":"G Wang","year":"2021","unstructured":"Wang, G. et al. Metabolic detection and systems analyses of pancreatic ductal adenocarcinoma through machine learning, lipidomics, and multi-omics. Sci. Adv. 7, eabh2724 (2021).","journal-title":"Sci. Adv."},{"key":"73871_CR54","doi-asserted-by":"publisher","first-page":"8882","DOI":"10.1073\/pnas.1307237110","volume":"110","author":"JJ Kamphorst","year":"2013","unstructured":"Kamphorst, J. J. et al. Hypoxic and Ras-transformed cells support growth by scavenging unsaturated fatty acids from lysophospholipids. Proc. Natl. Acad. Sci. USA 110, 8882\u20138887 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"73871_CR55","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1146\/annurev.biochem.73.011303.073731","volume":"73","author":"I Ishii","year":"2004","unstructured":"Ishii, I., Fukushima, N., Ye, X. & Chun, J. Lysophospholipid receptors: signaling and biology. Annu. Rev. Biochem 73, 321\u2013354 (2004).","journal-title":"Annu. Rev. Biochem"},{"key":"73871_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117443","volume":"247","author":"P Liu","year":"2020","unstructured":"Liu, P. et al. The mechanisms of lysophosphatidylcholine in the development of diseases. Life Sci. 247, 117443 (2020).","journal-title":"Life Sci."},{"key":"73871_CR57","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1111\/cas.14689","volume":"112","author":"N Jinno","year":"2021","unstructured":"Jinno, N. et al. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer. Cancer Sci. 112, 668\u2013678 (2021).","journal-title":"Cancer Sci."},{"key":"73871_CR58","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1136\/gutjnl-2020-323476","volume":"71","author":"F Chen","year":"2022","unstructured":"Chen, F. et al. Integrated analysis of the faecal metagenome and serum metabolome reveals the role of gut microbiome-associated metabolites in the detection of colorectal cancer and adenoma. Gut 71, 1315 (2022).","journal-title":"Gut"},{"key":"73871_CR59","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1038\/s41591-019-0559-3","volume":"25","author":"M Poyet","year":"2019","unstructured":"Poyet, M. et al. A library of human gut bacterial isolates paired with longitudinal multiomics data enables mechanistic microbiome research. Nat. Med. 25, 1442\u20131452 (2019).","journal-title":"Nat. Med."},{"key":"73871_CR60","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1007\/s13361-016-1469-y","volume":"27","author":"AC Schrimpe-Rutledge","year":"2016","unstructured":"Schrimpe-Rutledge, A. C., Codreanu, S. G., Sherrod, S. D. & McLean, J. A. Untargeted metabolomics strategies-challenges and emerging directions. J. Am. Soc. Mass Spectrom. 27, 1897\u20131905 (2016).","journal-title":"J. Am. Soc. Mass Spectrom."},{"key":"73871_CR61","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1038\/s41596-020-0341-5","volume":"15","author":"F Zheng","year":"2020","unstructured":"Zheng, F. et al. Development of a plasma pseudotargeted metabolomics method based on ultra-high-performance liquid chromatography\u2013mass spectrometry. Nat. Protoc. 15, 2519\u20132537 (2020).","journal-title":"Nat. Protoc."},{"key":"73871_CR62","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","volume":"25","author":"H Li","year":"2009","unstructured":"Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754\u20131760 (2009).","journal-title":"Bioinformatics"},{"key":"73871_CR63","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/bioinformatics\/btr670","volume":"28","author":"V Boeva","year":"2012","unstructured":"Boeva, V. et al. Control-FREEC: a tool for assessing copy number and allelic content using next-generation sequencing data. Bioinformatics 28, 423\u2013425 (2012).","journal-title":"Bioinformatics"},{"key":"73871_CR64","doi-asserted-by":"crossref","unstructured":"Domingo-Almenara, X., Montenegro-Burke, J. R., Benton, H. P. & Siuzdak, G. Annotation: a computational solution for streamlining metabolomics analysis. Anal. Chem. 90, 480 (2018).","DOI":"10.1021\/acs.analchem.7b03929"},{"key":"73871_CR65","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/nmeth.3047","volume":"11","author":"NE Sanjana","year":"2014","unstructured":"Sanjana, N. E., Shalem, O. & Zhang, F. Improved vectors and genome-wide libraries for CRISPR screening. Nat. Methods 11, 783\u2013784 (2014).","journal-title":"Nat. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73871-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73871-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:26:28Z","timestamp":1785036388000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73871-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73871"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73871-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Xingting Guo, Xudong Dai, and Kai Lin are employees of Precogify Pharmaceuticals. The remaining authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7004"}}